TY - JOUR
T1 - Higher Serum Vitamin D Concentrations Are Longitudinally Associated with Better Global Quality of Life and Less Fatigue in Colorectal Cancer Survivors up to 2 Years after Treatment
AU - Koole, Janna L.
AU - Bours, Martijn J. L.
AU - van Roekel, Eline H.
AU - Breedveld-Peters, Jose J. L.
AU - van Duijnhoven, Franzel J. B.
AU - van den Ouweland, Jody
AU - Breukink, Stephanie O.
AU - Janssen-Heijnen, Maryska L. G.
AU - Keulen, Eric T. P.
AU - Weijenberg, Matty P.
N1 - Funding Information:
The EnCoRe study was supported by grants from the Stichting Alpe d'HuZes within the research program “Leven met kanker” of the Dutch Cancer Society (Grant Nos. UM-2010-4867 and UM-2012-5653), by grants from Kankeronderzoekfonds Limburg as part of Health Foundation Limburg (Grant No. 00005739), and by a grant from Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund International grant program (grant number 2016/1620).
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/6
Y1 - 2020/6
N2 - Background: Vitamin D status may be an important determinant of health-related quality of life of colorectal cancer survivors. The current study investigated longitudinal associations between serum 25-hydroxyvitamin D-3 (25OHD(3)) concentrations and quality of life in stage I-III colorectal cancer survivors up to 2 years after treatment.Methods: Patients with colorectal cancer (n = 261) were included upon diagnosis. Home visits (including blood sampling) were performed at diagnosis and at 6 weeks, 6months, 1 year, and 2 years after treatment. Serum 25OHD(3) concentrations were measured using LC/MS-MS and adjusted for season. Validated questionnaires were used to assess global quality of life and cognitive functioning (EORTC-QLQ-C30), fatigue (EORTC-QLQ-C30 andChecklist Individual Strength, CIS), and depression and anxiety (Hospital Anxiety and Depression Scale). Statistical analyses were performed using linear mixed models and adjusted for sex, age, time since diagnosis, therapy, comorbidities, physical activity, and body mass index.Results: At diagnosis, 45% of patients were vitamin D deficient (Conclusions: Higher concentrations of 25OHD(3) were longitudinally associated with better global quality of life and less fatigue in colorectal cancer survivors.Impact: This study suggests that higher 25OHD(3) concentrations may be beneficial for colorectal cancer survivors. Future intervention studies are needed to corroborate these findings.
AB - Background: Vitamin D status may be an important determinant of health-related quality of life of colorectal cancer survivors. The current study investigated longitudinal associations between serum 25-hydroxyvitamin D-3 (25OHD(3)) concentrations and quality of life in stage I-III colorectal cancer survivors up to 2 years after treatment.Methods: Patients with colorectal cancer (n = 261) were included upon diagnosis. Home visits (including blood sampling) were performed at diagnosis and at 6 weeks, 6months, 1 year, and 2 years after treatment. Serum 25OHD(3) concentrations were measured using LC/MS-MS and adjusted for season. Validated questionnaires were used to assess global quality of life and cognitive functioning (EORTC-QLQ-C30), fatigue (EORTC-QLQ-C30 andChecklist Individual Strength, CIS), and depression and anxiety (Hospital Anxiety and Depression Scale). Statistical analyses were performed using linear mixed models and adjusted for sex, age, time since diagnosis, therapy, comorbidities, physical activity, and body mass index.Results: At diagnosis, 45% of patients were vitamin D deficient (Conclusions: Higher concentrations of 25OHD(3) were longitudinally associated with better global quality of life and less fatigue in colorectal cancer survivors.Impact: This study suggests that higher 25OHD(3) concentrations may be beneficial for colorectal cancer survivors. Future intervention studies are needed to corroborate these findings.
KW - HEALTH-RELATED QUALITY
KW - D DEFICIENCY
KW - D SUPPLEMENTATION
KW - HOSPITAL ANXIETY
KW - DEPRESSION
KW - DIAGNOSIS
KW - QUESTIONNAIRE
KW - DYSFUNCTIONS
KW - CHEMOTHERAPY
KW - METAANALYSIS
U2 - 10.1158/1055-9965.epi-19-1522
DO - 10.1158/1055-9965.epi-19-1522
M3 - Article
C2 - 32245785
SN - 1055-9965
VL - 29
SP - 1135
EP - 1144
JO - Cancer Epidemiology Biomarkers & Prevention
JF - Cancer Epidemiology Biomarkers & Prevention
IS - 6
ER -